GenVault Announces Supply Agreement With Life Technologies

CARLSBAD, Calif., Dec. 9  /PRNewswire/ -- GenVault Corporation (Carlsbad, CA) today announces a supply and resale agreement with Life Technologies Corporation (NASDAQ:LIFE), under which Life Technologies will have non-exclusive access to GenTegra(TM) DNA technology. This technology platform comes in several formats that are consistent with Life Technologies' on-going efforts to promote the development and delivery of products in ways that help to protect and preserve the environment.

"We are very pleased with Life Technologies' decision to adopt the GenTegra(TM) DNA technology platform," said Dr. David Wellis, President and CEO of GenVault Corporation.

"By adopting the GenTegra(TM) DNA technology platform, we will be able to store and transport purified DNA from several of our products as well as make this technology available for use by our customers," said Nathan Wood, Vice President, Genomic Technologies, at Life Technologies Corporation. "This technology allows us to eliminate much of the waste associated with these processes, which promotes a safer and cleaner environment."

Since its introduction in 2008, GenTegra(TM) DNA has been extensively tested and validated by scientists around the world.  The major advantages of using GenTegra DNA for storage and transport of purified DNA at ambient temperature include the reduction of the cost, waste and complexity associated with conventional dry ice shipments and freezer storage.  In addition, the elimination of multiple freeze/thaw cycles for samples which are accessed frequently also helps ensure the continued integrity of the DNA samples and generates more accurate data in downstream applications.

"Environmental sustainability is a key focus for us.  Life Technologies' decision to adopt GenVault's GenTegra(TM) DNA to improve their internal and customer efficiencies will change the way DNA is managed in the future," said Dr. Wellis. "This announcement is tangible evidence of our success in moving GenVault squarely into the center of the much larger biosample stabilization, storage and transport markets.  We look forward to extending the reach of our GenTegra(TM) technology platform into additional markets, formats and applications, including RNA in the fourth quarter of 2009," continued Dr. Wellis.

About GenVault

GenVault is the global leader in providing risk free biosample workflow, transport, and storage solutions for genomic medicine, discovery and identification. Today, GenVault is empowering  pharmaceutical companies, medical centers, academic institutions and law enforcement agencies to more fully leverage the rapidly growing genomics industry. As a scalable, reliable and environmentally friendly alternative to traditional freezers and DNA purification systems, the company's dry-state platform enables the extraction, preservation, recovery, and distribution of biosamples at ambient temperature. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. From GenPlates to the Dynamic Archive, GenVault is continuously developing and refining best practices biosample management and preservation. For more information visit GenVault at http://www.genvault.com/.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

  David Wellis, Ph.D
  http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91851




  CONTACT:
  David Wellis, Ph.D.
  President  & CEO
  [phone]
  

DATASOURCE: GenVault Corporation



CONTACT:  David Wellis, Ph.D., President & CEO of GenVault Corporation,

[phone], 



Web Site:  http://www.genvault.com/ 

Copyright